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Background
The incidence of chronic pancreatitis (CP) varies between
4 and 23/100.000 in different populations and a tenfold
higher prevalence. Current diagnostic tests such as trans-
abdominal ultrasound and CA 19-9 can distinguish
between pancreatic cancer (PDAC) and chronic pancreati-
tis (CP) in only about two thirds of patients. CA19-9 has
been reported to discriminate between pancreatic cancer
patients and healthy controls with a sensitivity of 0.80
(95 % CI 0.787-0.83) and a specificity of 0.80 (95 % CI
0.78-0.82). Therefore more sensitive biomarkers for the
early detection of pancreatic cancer would be urgently
needed. Our aim was to identify a panel of plasma meta-
bolite biomarkers for this diagnostic purpose.
Materials and methods
For a case-control study, 914 subjects were retrospectively
recruited from three tertiary referral centers with either
pancreatic cancer (n=271), chronic pancreatitis (n=282),
liver cirrhosis (n=100), or healthy as well as non-pancreatic
disease controls (n=261). An initial exploratory study
(n=201) was followed by a two-center identification study
(n=474; training set) and a third validation test set
(n=239). Metabolomic profiles of plasma and serum
samples were generated using the comprehensive metabo-
lome platform including lipidomics ((MxP® Broad Profil-
ing, MxP® Steroids, MxP® - gas chromatography-mass
spectrometry (GC-MS) and liquid chromatography-
tandem mass spectrometry (LC-MS/MS) ) identifying 477
metabolites.
Results
A consistent multimarker 10-metabolite panel (including
sphingomyelin and ceramide) was identified by the Elastic
Net algorithm providing an area under the curve (AUC) of
up to 0.96 [95% CI 0.93-0.98] (pancreatic cancer vs.
chronic pancreatitis). With a fixed sensitivity of 88% and
an estimated incidence of 1.95 for pancreatic cancer a test
specificity of 93.8% [95% CI84-98%] for the training set
and of 91.3% [95% CI 76-94%] for the validation (test) set
was reached with a negative predictive value (NPV) of
99.75% [95% CI 99.7-99.8%]. Pancreatic cancer can not
only be detected but also distinguished from chronic
pancreatitis when still in a resectable (i.e. early) stage.
Conclusion
These results indicate that a plasma metabolite biomarker
panel including important metabolites identified by the
lipidomics platform can be used to accurately distinguish
between pancreatic cancer and chronic pancreatitis.
Sphingolipids are characterized by the presence of a parti-
cular aliphatic amino alcohol, sphingosine. Cleavage of
sphingomyelins by sphingomyelinase generates ceramide,
which promotes apoptosis, cell cycle arrest and cellular
senescence. It also permits the development of a promis-
ing diagnostic plasma biomarker assay for the detection
pancreatic cancer in high risk cohorts.
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